Cytori Therapeutics Company Profile (NASDAQ:CYTX)

About Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics logoCytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CYTX
  • CUSIP: 23283K10
  • Web: www.cytori.com
Capitalization:
  • Market Cap: $36.05 million
  • Outstanding Shares: 32,478,000
Average Prices:
  • 50 Day Moving Avg: $1.07
  • 200 Day Moving Avg: $1.33
  • 52 Week Range: $0.90 - $2.29
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.47
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $10.07 million
  • Price / Sales: 3.58
  • Book Value: $0.31 per share
  • Price / Book: 3.58
Profitability:
  • EBIDTA: ($18,720,000.00)
  • Net Margins: -491.71%
  • Return on Equity: -177.92%
  • Return on Assets: -62.73%
Debt:
  • Debt-to-Equity Ratio: 1.28%
  • Current Ratio: 0.94%
  • Quick Ratio: 0.62%
Misc:
  • Average Volume: 569,678 shs.
  • Beta: 3.05
  • Short Ratio: 2.34
 
Frequently Asked Questions for Cytori Therapeutics (NASDAQ:CYTX)

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Shares of Cytori Therapeutics reverse split on Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) released its quarterly earnings results on Thursday, May, 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.05. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $2.32 million. Cytori Therapeutics had a negative net margin of 491.71% and a negative return on equity of 177.92%. The firm's revenue was down 53.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.03) earnings per share. View Cytori Therapeutics' Earnings History.

Where is Cytori Therapeutics' stock going? Where will Cytori Therapeutics' stock price be in 2017?

2 equities research analysts have issued 1 year price targets for Cytori Therapeutics' stock. Their forecasts range from $2.30 to $10.00. On average, they expect Cytori Therapeutics' share price to reach $6.15 in the next year. View Analyst Ratings for Cytori Therapeutics.

What are analysts saying about Cytori Therapeutics stock?

Here are some recent quotes from research analysts about Cytori Therapeutics stock:

  • 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (7/12/2017)
  • 2. Maxim Group analysts commented, "With the closure of the Azaya acquisition announced this morning, we now assume a 15% market share and 35% royalty rate for the $300M European Liposomal Doxorubicin market with the first year of commercial sales in 2019. We recognize that a US fast track strategy could put Cytori's Doxorubicin in the US market (even before Europe) but for conservatism we do not assume US revenues in our model (nor do we assume Japan, or any other geographies which will likely evolve as well). We believe our 15% share and 35% royalty rates are both realistic (and market share could be conservative). The result of these changes is our valuation target now changes from $6 to $10 per share." (2/15/2017)

Who are some of Cytori Therapeutics' key competitors?

Who are Cytori Therapeutics' key executives?

Cytori Therapeutics' management team includes the folowing people:

  • David M. Rickey, Independent Chairman of the Board
  • Marc H. Hedrick M.D., President, Chief Executive Officer, Director
  • Tiago Girao, Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
  • Seijiro N. Shirahama, President , Asia Pacific
  • John David Harris, Vice President, General Manager - Cell Therapy
  • Jeremy Bragg Hayden, Vice President - Business Development, General Counsel
  • Mark Marino M.D., Chief Medical Officer
  • Gregg A. Lapointe, Director
  • Richard James Hawkins, Independent Director
  • Gary A. Lyons, Independent Director

How do I buy Cytori Therapeutics stock?

Shares of Cytori Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytori Therapeutics' stock price today?

One share of Cytori Therapeutics stock can currently be purchased for approximately $1.11.


MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  278
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cytori Therapeutics (NASDAQ:CYTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.15 (454.05% upside)

Analysts' Ratings History for Cytori Therapeutics (NASDAQ:CYTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Maxim GroupSet Price TargetBuy$10.00HighView Rating Details
5/15/2017B. RileyReiterated RatingBuy$2.30HighView Rating Details
6/28/2016Roth CapitalReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Cytori Therapeutics (NASDAQ:CYTX)
Earnings by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Earnings History by Quarter for Cytori Therapeutics (NASDAQ CYTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.31)($0.26)$2.32 million$0.60 millionViewN/AView Earnings Details
3/23/2017Q4 16($0.23)($0.24)$3.36 million$1.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.24)($0.26)$2.85 million$2.61 millionViewListenView Earnings Details
8/4/2016Q216($0.39)($0.43)$2.50 million$1.10 millionViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.41)$2.05 million$2.90 millionViewListenView Earnings Details
3/3/2016Q4($0.04)($0.03)$2.90 million$1.56 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.04)$5.27 million$2.48 millionViewN/AView Earnings Details
8/6/2015Q215($0.03)($0.03)$2.50 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.07)$2.44 million$0.90 millionViewListenView Earnings Details
3/12/2015Q4 14($0.08)($0.08)$3.10 million$2.47 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.09)($0.12)$4.31 million$1.10 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.11)($0.15)$2.76 million$0.94 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.14)$2.87 million$1.03 millionViewN/AView Earnings Details
3/12/2014Q413($0.12)($0.14)$4.37 million$2.71 millionViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.08)$3.17 million$8.70 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.13)($0.16)$2.88 million$6.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.11)ViewN/AView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.25 million$1.31 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytori Therapeutics (NASDAQ:CYTX)
2017 EPS Consensus Estimate: ($0.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cytori Therapeutics (NASDAQ:CYTX)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 8.70%
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Institutional Ownership by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Insider Trades by Quarter for Cytori Therapeutics (NASDAQ:CYTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016John David HarrisVPBuy2,500$2.03$5,075.00View SEC Filing  
6/14/2016Gail K NaughtonDirectorBuy1,000$2.10$2,100.00View SEC Filing  
5/13/2016John David HarrisVPBuy2,000$2.71$5,420.00View SEC Filing  
3/9/2016David RickeyDirectorBuy150,000$0.19$28,500.00View SEC Filing  
9/3/2015Tommy G ThompsonDirectorBuy25,449$0.37$9,416.13View SEC Filing  
9/2/2015Jeremy B HaydenVPBuy8,200$0.36$2,952.00View SEC Filing  
8/28/2015David RickeyDirectorBuy56,000$0.31$17,360.00View SEC Filing  
8/28/2015Marc H HedrickCEOBuy11,200$0.31$3,472.00View SEC Filing  
8/27/2015David RickeyDirectorBuy75,000$0.31$23,250.00View SEC Filing  
8/21/2015David RickeyDirectorBuy50,000$0.38$19,000.00View SEC Filing  
8/21/2015Marc H HedrickCEOBuy5,000$0.38$1,900.00View SEC Filing  
8/20/2015Marc H HedrickCEOBuy10,000$0.40$4,000.00View SEC Filing  
8/19/2015David RickeyDirectorBuy48,600$0.39$18,954.00View SEC Filing  
8/19/2015Steven KestenVPBuy6,000$0.39$2,340.00View SEC Filing  
8/18/2015David RickeyDirectorBuy51,400$0.39$20,046.00View SEC Filing  
8/18/2015Marc H HedrickCEOBuy10,000$0.39$3,900.00View SEC Filing  
8/18/2015Tiago GiraoCFOBuy25,000$0.39$9,750.00View SEC Filing  
11/13/2014David RickeyDirectorBuy20,000$0.47$9,400.00View SEC Filing  
11/12/2014David RickeyDirectorBuy200,000$0.39$78,000.00View SEC Filing  
11/12/2014Tiago GiraoCFOBuy60,000$0.39$23,400.00View SEC Filing  
11/11/2014Tiago GiraoCFOBuy15,889$0.39$6,196.71View SEC Filing  
6/5/2014David RickeyDirectorBuy30,000$2.34$70,200.00View SEC Filing  
9/12/2013David RickeyDirectorBuy7,100$2.55$18,105.00View SEC Filing  
9/11/2013David RickeyDirectorBuy2,000$2.58$5,160.00View SEC Filing  
9/9/2013David RickeyDirectorBuy5,000$2.31$11,550.00View SEC Filing  
9/5/2013David RickeyDirectorBuy2,000$2.24$4,480.00View SEC Filing  
9/3/2013David RickeyDirectorBuy7,000$2.14$14,980.00View SEC Filing  
8/30/2013Tommy G ThompsonDirectorBuy5,000$2.14$10,700.00View SEC Filing  
12/19/2012Lloyd H DeanDirectorBuy25,000$2.85$71,250.00View SEC Filing  
12/19/2012Marc H HedrickPresidentBuy10,000$2.85$28,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cytori Therapeutics (NASDAQ:CYTX)
Latest Headlines for Cytori Therapeutics (NASDAQ:CYTX)
Source:
DateHeadline
americanbankingnews.com logoZacks Investment Research Lowers Cytori Therapeutics Inc (CYTX) to Hold
www.americanbankingnews.com - July 12 at 7:10 PM
americanbankingnews.com logoCytori Therapeutics Inc (NASDAQ:CYTX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:04 PM
streetinsider.com logoCytori Therapeutics (CYTX) Says AMA Approves New Category III ... - StreetInsider.com
www.streetinsider.com - July 10 at 5:39 PM
finance.yahoo.com logoAmerican Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma Therapy
finance.yahoo.com - July 10 at 5:39 PM
nasdaq.com logoAre Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock? - Nasdaq
www.nasdaq.com - July 8 at 10:07 AM
streetinsider.com logoCytori Therapeutics (CYTX) Issued Key Patents for Scleroderma - StreetInsider.com
www.streetinsider.com - July 8 at 10:07 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock?
finance.yahoo.com - July 8 at 10:07 AM
streetinsider.com logoPre-Open Movers 07/06: (HSNI) (BGNE) (CYTX) Higher; (EGLT) (TAHO) (AZZ) Lower (more...)
www.streetinsider.com - July 6 at 3:16 PM
finance.yahoo.com logoETFs with exposure to Cytori Therapeutics, Inc. : July 5, 2017
finance.yahoo.com - July 5 at 6:27 PM
finance.yahoo.com logoCytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin America
finance.yahoo.com - June 14 at 5:36 PM
streetinsider.com logoCytori Therapeutics (CYTX) Publishes Long-Term Safety Data on ... - StreetInsider.com
www.streetinsider.com - June 8 at 10:41 PM
rttnews.com logoCytori Publishes Long Term Safety Data On Technology For Breast Reconstruction
www.rttnews.com - June 8 at 10:06 AM
finance.yahoo.com logoLong Term Safety Data Published on Cytori Technology for Breast Reconstruction After Oncologic Surgery & Radiation Therapy
finance.yahoo.com - June 8 at 10:06 AM
finance.yahoo.com logoETFs with exposure to Cytori Therapeutics, Inc. : June 6, 2017
finance.yahoo.com - June 6 at 4:56 PM
americanbankingnews.com logoValuEngine Lowers Cytori Therapeutics Inc (CYTX) to Strong Sell
www.americanbankingnews.com - June 4 at 9:16 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) PT Set at $10.00 by Maxim Group
www.americanbankingnews.com - June 1 at 11:02 PM
globenewswire.com logoCytori to Introduce Next-Generation Celution® Technology - GlobeNewswire (press release)
globenewswire.com - June 1 at 10:17 PM
finance.yahoo.com logoCytori to Introduce Next-Generation Celution® Technology
finance.yahoo.com - June 1 at 5:16 PM
finance.yahoo.com logoCytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Trial
finance.yahoo.com - May 31 at 9:58 AM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Short Interest Update
www.americanbankingnews.com - May 28 at 7:16 AM
finance.yahoo.com logoETFs with exposure to Cytori Therapeutics, Inc. : May 25, 2017
finance.yahoo.com - May 25 at 6:25 PM
finance.yahoo.com logoCytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 12:38 PM
finance.yahoo.com logoCytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial
finance.yahoo.com - May 23 at 12:32 PM
finance.yahoo.com logoCytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor Conference
finance.yahoo.com - May 16 at 12:06 PM
americanbankingnews.com logoFY2019 EPS Estimates for Cytori Therapeutics Inc Lowered by B. Riley (CYTX)
www.americanbankingnews.com - May 15 at 10:10 AM
americanbankingnews.com logoB. Riley Reaffirms "Buy" Rating for Cytori Therapeutics Inc (CYTX)
www.americanbankingnews.com - May 14 at 10:14 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Sees Significant Drop in Short Interest
www.americanbankingnews.com - May 13 at 7:44 AM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 12 at 7:41 PM
finance.yahoo.com logoEdited Transcript of CYTX earnings conference call or presentation 11-May-17 9:30pm GMT
finance.yahoo.com - May 12 at 5:10 PM
americanbankingnews.com logoCytori Therapeutics Inc (CYTX) Issues Earnings Results
www.americanbankingnews.com - May 12 at 3:12 PM
americanbankingnews.com logoQ1 2017 Earnings Estimate for Cytori Therapeutics Inc (CYTX) Issued By B. Riley
www.americanbankingnews.com - May 12 at 7:48 AM
rttnews.com logoEARNINGS SUMMARY: Details of Cytori Therapeutics Inc. Q1 Earnings Report
www.rttnews.com - May 11 at 10:18 PM
finance.yahoo.com logoCytori reports 1Q loss
finance.yahoo.com - May 11 at 10:18 PM
finance.yahoo.com logoCytori Reports First Quarter 2017 Business and Financial Results
finance.yahoo.com - May 11 at 5:17 PM
finance.yahoo.com logoOne Year Follow Up of Cytori Cell Therapy™ in Investigator Erectile Dysfunction Trial
finance.yahoo.com - May 10 at 4:49 PM
finance.yahoo.com logoCytori Therapeutics Announces Inducement Grants for New Employees
finance.yahoo.com - May 5 at 9:53 PM
americanbankingnews.com logoCytori Therapeutics (CYTX) Receives News Sentiment Rating of 0.35
www.americanbankingnews.com - May 3 at 1:24 PM
finance.yahoo.com logoCytori to Webcast First Quarter Financial Results on May 11
finance.yahoo.com - April 27 at 5:10 PM
americanbankingnews.com logoSomewhat Negative Press Coverage Somewhat Unlikely to Affect Cytori Therapeutics (CYTX) Share Price
www.americanbankingnews.com - April 24 at 2:01 PM
americanbankingnews.com logoCritical Media Coverage Very Unlikely to Impact Cytori Therapeutics (CYTX) Share Price
www.americanbankingnews.com - April 21 at 7:47 AM
americanbankingnews.com logoCytori Therapeutics (CYTX) Earns Media Impact Score of 0.29
www.americanbankingnews.com - April 18 at 1:54 PM
americanbankingnews.com logoCytori Therapeutics (CYTX) Getting Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 15 at 1:21 PM
streetinsider.com logoCytori Therapeutics (CYTX) IDE Approved by FDA for Pilot Clinical Trial to Evaluate Cytori Cell Therapy
www.streetinsider.com - April 11 at 12:56 PM
finance.yahoo.com logoCytori Therapeutics' stock plunges toward record low after stock offering prices at deep discount
finance.yahoo.com - April 11 at 12:56 PM
finance.yahoo.com logoCytori Therapeutics Stock Sliding on Offering Price Discount
finance.yahoo.com - April 11 at 12:56 PM
seekingalpha.com logoCytori Therapeutics -36% after pricing 8.6M-share offering at $1.10
seekingalpha.com - April 11 at 9:51 AM
finance.yahoo.com logoETFs with exposure to Cytori Therapeutics, Inc. : April 10, 2017
finance.yahoo.com - April 10 at 4:29 PM
finance.yahoo.com logoCytori Get FDA Approval for Clinical Burn Trial
finance.yahoo.com - April 10 at 4:29 PM
finance.yahoo.com logoCytori Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 10 at 4:29 PM
finance.yahoo.com logoCytori Receives U.S. FDA Approval for Burn Clinical Trial Related to BARDA Contract
finance.yahoo.com - April 10 at 12:03 PM

Social

Chart

Cytori Therapeutics (CYTX) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff